Literature DB >> 22562706

Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.

Ceyla Konca Degertekin, Uğur Coşkun, Füsun Baloş Törüner, Müjde Aktürk, Umut Demirci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22562706     DOI： 10.1007/s12020-012-9683-2

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  4 in total

1.  Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.

Authors:  I Tamaskar; R Bukowski; P Elson; A G Ioachimescu; L Wood; R Dreicer; T Mekhail; J Garcia; B I Rini
Journal:  Ann Oncol       Date:  2007-10-24       Impact factor: 32.976

2.  Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

Authors:  James H Finke; Brian Rini; Joanna Ireland; Patricia Rayman; Amy Richmond; Ali Golshayan; Laura Wood; Paul Elson; Jorge Garcia; Robert Dreicer; Ronald Bukowski
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

3.  Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation.

Authors:  Hideaki Miyake; Toshifumi Kurahashi; Kazuki Yamanaka; Yutaka Kondo; Mototsugu Muramaki; Atsushi Takenaka; Taka-Aki Inoue; Masato Fujisawa
Journal:  Urol Oncol       Date:  2009-11-13       Impact factor: 3.498

4.  Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

Authors:  Mathis Grossmann; Erosha Premaratne; Jayesh Desai; Ian D Davis
Journal:  Clin Endocrinol (Oxf)       Date:  2008-04-03       Impact factor: 3.478
  4 in total
  4 in total

Review 1.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

2.  Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma.

Authors:  Juliette Eroukhmanoff; Frederic Castinetti; Nicolas Penel; Sebastien Salas
Journal:  BMC Cancer       Date:  2016-08-24       Impact factor: 4.430

3.  Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia.

Authors:  Jie Sun; Juan Hu; Yan Huang; Shuang-Wei Ying; Xiao-Yan Han; Yan-Long Zheng; He Huang
Journal:  Chin Med J (Engl)       Date:  2016-10-20       Impact factor: 2.628

Review 4.  Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment.

Authors:  Hala Ahmadieh; Ibrahim Salti
Journal:  Biomed Res Int       Date:  2013-10-27       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.